The aetiology of major depressive disorder (MDD) has been linked, variously, to brain monoaminergic neuronal dysfunction, alterations in monoamine receptor sensitivity and stress-induced activation of the hypothalamic-pituitary-adrenal axis. In an effort to unify these observations, Duman et al. 1 recently proposed the neurotrophic hypothesis of depression. Duman posits that vulnerability to depression induced by stress-induced activation of the HPA-axis and the therapeutic action of antidepressant treatments are both due to intracellular mechanisms that decrease or increase, respectively, neurotrophic factors necessary for the survival and function of particular neurons. 1 While most attention has focused on brain-derived neurotophic factor, in an elegant study, leptin was recently demonstrated to act as a neurotrophic factor in the mouse hypothalamus, rapidly influencing neuronal arborisation. 2 With this as a basis, and given that we have previously demonstrated leptin production by the brain in healthy subjects, 3, 4 we hypothesised that patients with MDD, controlled for gender, age and obesity, would exhibit a reduction in brain leptin production.
Twenty patients (8 males/12 females, aged 4573 years, body mass index (BMI) 2771) fulfilling the DSM-IV diagnostic criteria for MDD and 20 healthy subjects (10 males/10 females, aged 4072 years, BMI 2671) were recruited following local media advertisement. Patients with depression were either newly diagnosed or currently untreated after a recent relapse. Following initial telephone screening, patients were interviewed by a psychiatrist utilising a structured clinical interview (Mini International Neuropsychiatric Interview (MINI)). Hamilton Depression Scale (17 item) and Beck Depression Inventory (BDI-1) were used to monitor severity. Eligibility for entry was determined by HamD > 18, BDI > 18, positive for major depression on MINI and assessed as having a significant major depression as the primary illness on interview by a psychiatrist. Patients with comorbid panic or anxiety disorders were included in the study if the primary diagnosis was depression and any panic/anxiety was secondary to their depression. All participants had a general medical review and examination by a medical practitioner to exclude any previously undiagnosed medical conditions. Exclusion criteria included coexistent physical illness and comorbid psychotic disorders, eating disorders, mental retardation, high suicide risk, cluster borderline personality disorders and epilepsy. The research protocol conformed to the relevant guidelines of the National Health and Medical Research Council of Australia and was approved by the Alfred Hospital Ethics Review Committee. Written informed consent was obtained from each subject prior to the study. The process of consent, to which an honest, open, and explicit patient information sheet was central, preserved the autonomy of the participants. Healthy volunteers were paid a nominal amount of US$75 for their participation. Following the study patients with MDD were referred to a psychiatrist for clinical management.
Blood samples were obtained simultaneously from the right internal jugular vein and brachial artery using percutaneously placed catheters as previously described. 5 Data are expressed as mean7s.e.m. For comparing data between patients and healthy subjects, Student's t-test or the Mann-Whitney test were used as appropriate. P < 0.05 was considered as statistically significant.
Brain leptin mRNA expression was determined from biopsy material obtained at autopsy from 10 subjects (age: 4675; BMI: 2671) at the Victorian Institute of Forensic Medicine (VIFM). The informed consent of the donor's next-of-kin was obtained before the autopsy and the VIFM Ethics Review Committee approved the protocol. All autopsies were performed no more than 48 h after death. There was no difference in the elapsed time (i.e. time between death and autopsy) between suicide victims and controls. A coronal slice of the hypothalamus between the mamillary bodies and optic chiasm was obtained and the tissue was snap frozen in liquid nitrogen. Leptin mRNA was isolated from tissue and was assessed by conventional RT-PCR. The identity of each PCR band was confirmed by automated sequencing.
Patients with MDD were significantly depressed with a mean HamD of 2671 (range 20-34) and a selfreport BDI of 3072 (range 20-42). Ten of the patients had a positive family history of depression. On average, patients had experienced 2.6 previous episodes of depression, with 68% having two or more previous episodes. In two subjects this was their first episode. Four of the population had duration of the current episode of less than 3 months whereas 50% had duration of current episode of greater than 12 months. Eight subjects described loss of appetite and six of the patients experienced weight loss during the current bout of depression. Arterial plasma leptin concentrations were not significantly different between healthy volunteers and patients with MDD (10.471.9 vs 13.072.2 ng/ml, respectively). In healthy subjects, indicative of significant brain leptin production, there occurred a positive veno-arterial concentration gradient across the brain (22.174.3%). The spillover of leptin into the internal jugular venous effluent was significantly reduced in patients with MDD (6.574.4%, P < 0.05; Figure 1a ). There occurred no significant association between weight or appetite loss and the internal jugular venous overflow of leptin in patients with MDD. Examination of leptin mRNA in the brain indicated that a signal of a predicted size of 366 bp was detected in brain tissue of donors that died from natural causes, predominantly sudden cardiac death, as well as in adipose tissue (positive control). However, leptin mRNA was not detectable in the human brain following suicide. Figure 1b shows a representative RT-PCR result of leptin expression in the hypothalamus of 10 donors.
The observations that ob/ob mice have reduced numbers of synapses in the arcuate nucleus and that leptin administration rapidly normalises synaptic density suggests that leptin mediated neuroplasticity may underly some of leptin's behavioral effects. 2 While the majority of support for the neurotrophic hypothesis of MDD rises from preclinical studies, our recent observation of global (i.e. noradrenergic, dopaminergic and serotonergic) reduction in both subcortical monoamine turnover and cerebral glucose utilisation in patients with MDD 4 is consistent with this hypothesis. 1 Of many endogenous neurotrophic factors, our experiments implicate leptin in the aetiology of MDD. 
